<DOC>
	<DOC>NCT02550964</DOC>
	<brief_summary>The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.</brief_summary>
	<brief_title>Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy Aged less than 19 years</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Hydroxychloroquine(HCQ)</keyword>
	<keyword>Chloroquine(CQ)</keyword>
	<keyword>Toxic Maculopathy</keyword>
</DOC>